

|

The United States and Canadian Academy of Pathology’s mission is to provide pathologists with high quality continuing medical education (CME) at all
levels of pathology practice and to reinforce and update attendees’ knowledge of pathology in their area(s) of interest and need in the understanding of
pathologic processes. This mission is accomplished by a broad CME program that includes lectures, seminars, symposia, interactive courses, question and
answer sessions, and online courses and teaching modules on various topics and forums of intellectual and professional interests. The participants engage
in presentation, discussion and critical evaluation of the scientific, technological and methodological advances in human health and disease.

The USCAP’s zero-tolerance policy for any real or perceived commercial bias in educational or scientific programs is a fundamental principle that guides
our interaction with industry. It is our goal to avoid even the appearance of a conflict of interest between the USCAP and industry.

USCAP policies are based upon the guidelines established by the Accreditation Council for Continuing Medical Education (ACCME). CME Programs at USCAP
meetings are developed and implemented primarily by the USCAP’s Education Committee. Industry has no role in selecting program topics, faculty, or course
directors, or influencing CME content. Industry influence or promotion of on-line CME activities is prohibited. All speakers must disclose, prior to
their presentation, if they or their spouse/partner have any significant financial or other relationship with any commercial entity, irrespective of their
presentation topic. This applies to current relationships as well as those for the previous twelve months. These disclosures are published in our
meeting materials before the presentations. Members of USCAP Committees must also make these same disclosures prior to their participation in committee
meetings where decisions are made regarding USCAP educational programs.

The USCAP benefits from its partnership with corporate sponsors who provide financial support for a variety of non-CME activities and programs. The USCAP
does not accept commercial support for any CME activity. The USCAP recognizes members’ concerns regarding industry involvement and the potential for
commercial bias, overt or otherwise. The USCAP regularly reviews and revises its guidelines that govern industry participation to ensure that they are
appropriate, comprehensive, and unambiguous. Commercial Exhibitors are required to sign letters of agreement explicitly stating that they have had no
input into decision making regarding selection of educational programs, content or faculty and that they understand and will adhere to USCAP guidelines.

The USCAP has revised its online evaluation forms to provide attendees with the opportunity to report any perceived commercial bias. The USCAP Education
Committee and CME Subcommittee, together with the USCAP staff, investigate and act on any infractions or perceptions of bias in a rigorous and impartial
manner. They may also seek further input on these or other ethical issues from the USCAP ad hoc Ethics Committee.

The USCAP values its partnership with industry. However, the USCAP will not compromise the independence and credibility of its scientific and CME
programs through its relationships with corporate sponsors. Appropriate guidelines, as well as input from attendees, are essential to maintain our
integrity as an organization and the confidence that pathology professionals have placed in the USCAP. Questions related to these issues may be addressed
to Dr. Bruce Smoller, Executive Vice-President of the USCAP: e-mail bruce@uscap.org.

August 12, 2009

Approved by the USCAP CME Subcommittee
Tarik Tihan, Director
Michele Bloomer
Gregory N. Fuller
Christina Isacson
Bradley Quade
|
|